Pint Pharma and Dyax Corp. Announce Partnership

Pint Pharma and Dyax Corp. Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America   Dyax Corp. a developer of novel biotherapeutics for unmet medical needs, and Pint Pharma (Pint) announced today a strategic partnership for the development and commercialization ...
> continue

Pint Pharma receives TRACE Anti-Bribery Compliance cert.

PINT PHARMA GmbH receives TRACE Anti-Bribery Compliance certification Pint Pharma GmbH, the rare disease experts in the Latin American market based in Vienna Austria gets certified by TRACE International, the leading non-profit organization aiming to increase commercial transparency for multinational companies and their commercial intermediaries by raising the standard of ...
> continue

Distribution Agreement for Remodulin™

Pint Pharma and Ferrer Internacional Announce Signing of Distribution Agreement for Remodulin™ (treprostinil) in Colombia
> continue

Cooperation agreement with PTC Pharmaceuticals

Pint Pharma announces cooperation agreement with PTC Pharmaceuticals to introduce, commercialize and bring forward Translarna™ (ataluren), a novel drug indicated for nonsense mutation Duchenne muscular dystrophy.  
> continue

To continue to the Website, you agree that you are a medical professional.

> Enter

Para continuar a la Página Web, usted debe confirmar que es un profesional médico.

> Entrar